Menggang Yu
University of Wisconsin-Madison
H-index: 45
North America-United States
Top articles of Menggang Yu
Abstract PO1-06-09: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersBig Ten Cancer …
Cancer Research
2024/5/2
YIA24-004: Liquid Biomarkers of Response to Radium-223 in Metastatic Prostate Cancer
Journal of the National Comprehensive Cancer Network
2024/4/5
Imatinib plus Cetuximab as a Window of Opportunity Clinical Trial in Head and Neck Cancer
International Journal of Radiation Oncology, Biology, Physics
2024/4/1
Menggang Yu
H-Index: 32
Safety and Toxicity of Iopofosine I-131 with External Beam Radiation Therapy (EBRT) in Recurrent or Metastatic Head and Neck Cancer (HNC): Results of a Phase 1 Study
International Journal of Radiation Oncology, Biology, Physics
2024/4/1
Randomized phase II selection design with order constrained strata
Biometrics
2024/3
Yi Chen
H-Index: 3
Menggang Yu
H-Index: 32
Robust sample weighting to facilitate individualized treatment rule learning for a target population
Biometrika
2024/3
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
The Oncologist
2024/2/7
Shawn Yu
H-Index: 1
Menggang Yu
H-Index: 32
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Nature Medicine
2024/1/19
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Cancer
2024/1/5
Corrections & amendments
2023
Smoking status, nicotine medication, vaccination, and COVID-19 hospital outcomes: findings from the COVID EHR cohort at the University of Wisconsin (CEC-UW) study
Nicotine and Tobacco Research
2023/6/1
Sean Kent
H-Index: 1
Hanna Kim
H-Index: 1
Menggang Yu
H-Index: 32
Andrew D Boyd
H-Index: 13
Li-Shiun Chen
H-Index: 65
Molecular classification of cancer site of origin and lineage.
2023/6/1
Yue Shi
H-Index: 4
John Floberg
H-Index: 9
Amy Taylor
H-Index: 32
Menggang Yu
H-Index: 32
Shuang Zhao
H-Index: 2
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer
Head & Neck
2023/5
Menggang Yu
H-Index: 32
Seungpyo Hong
H-Index: 34
The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT‐01)
Cancer
2023/5/1
Menggang Yu
H-Index: 32
Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients
Radiotherapy and oncology
2023/5/1
Antonia E Wuschner
H-Index: 1
Poonam Yadav
H-Index: 6
Menggang Yu
H-Index: 32
Gary E Christensen
H-Index: 28
Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01)
Annals of surgery
2023/5/1
Menggang Yu
H-Index: 32
A generalizability score for aggregate causal effect
Biostatistics
2023/4/1
Abstract P5-02-47: Quantitative proteomic analysis of plasma exosomes from patients with advanced hormone receptor-positive/HER2-negative breast cancer receiving palbociclib …
Cancer Research
2023/3/1
Ziwei Zhang
H-Index: 1
Xiuyuan Ma
H-Index: 3
Anne Blaes
H-Index: 21
Menggang Yu
H-Index: 32
Yu Gao
H-Index: 14
Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
Cancer Research
2023/3/1
Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder …
2023/2/20
